Welcome to our dedicated page for Point Biopharma Global news (Ticker: PNT), a resource for investors and traders seeking the latest updates and insights on Point Biopharma Global stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Point Biopharma Global's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Point Biopharma Global's position in the market.
POINT Biopharma Global Inc. (NASDAQ: PNT) announced promising preclinical results for its PNT2004 program, targeting fibroblast activation protein-alpha (FAP-alpha) in cancer treatment. This data shows best-in-class tumor targeting with minimal normal tissue retention, achieving complete tumor regression and enhanced survival in animal models. The company has amended its licensing agreement with Bach Biosciences to expand the application of its technology. A Phase 1 clinical trial is anticipated in 1H2022, aiming to leverage the precision radiopharmaceutical for effective cancer therapies.
POINT Biopharma Global Inc. (NASDAQ: PNT) announced a significant milestone in its Phase 3 SPLASH trial for PNT2002, targeting Metastatic Castrate Resistant Prostate Cancer (mCRPC). The trial's safety and dosimetry run-in phase successfully met all pre-specified criteria, paving the way for randomization to commence without changes to the design. Enrollment has started in Canada, with plans to include additional countries. The study aims to enroll around 400 patients, examining PNT2002 against Abiraterone or Enzalutamide, with primary endpoints focusing on radiographic progression-free survival.
Convergent Therapeutics and POINT Biopharma Global Inc. have launched a collaboration to assess the efficacy of the combination therapy using CONV 01-α and PNT2002 for treating progressive metastatic castration-resistant prostate cancer (mCRPC). The Phase I/II trial, currently enrolling up to 33 patients, aims to determine the maximum tolerated dose (MTD) and evaluate the response rate in patients exhibiting a significant decline in prostate-specific antigen (PSA). This collaboration aims to improve patient outcomes leveraging dual-targeted radiopharmaceutical therapy.
POINT Biopharma Global Inc. (PNT) announced a supply agreement with NorthStar Medical Radioisotopes for the therapeutic radioisotope actinium-225 (Ac-225). The partnership aims to enhance the availability of Ac-225 for investigational studies related to PNT's prostate cancer therapies, including PNT2001 and PNT2004. NorthStar plans to leverage its advanced electron accelerator technology to produce Ac-225, addressing the current supply limitations of this critical radioisotope. This agreement signifies a key step in advancing targeted radiotherapeutics for cancer treatment.
POINT Biopharma Global Inc. (NASDAQ: PNT) announced that CEO Dr. Joe McCann will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast of the presentation will be available on the company's website starting at 7:00 am ET on September 13, 2021, with an archived replay accessible for 30 days. POINT Biopharma specializes in radiopharmaceuticals aimed at treating cancer, focusing on clinical development and commercialization of radioligands.
On August 13, 2021, POINT Biopharma Global Inc. (NASDAQ: PNT) announced financial results for Q2 2021, reporting a net loss of $8.8 million and cash reserves of $273.7 million following a successful business combination with Therapeutics Acquisition Corp. The company completed enrollment for a Phase 3 study of PNT2002, targeting metastatic castration-resistant prostate cancer. The SPLASH study aims to evaluate the drug's efficacy with top-line results expected in mid-2023. POINT is also advancing other radioligand therapies and has expanded its leadership team.
POINT Biopharma Global Inc. (NASDAQ: PNT) has successfully completed enrollment and initial dosing of the 25-patient safety and dosimetry lead-in for its Phase 3 SPLASH study, evaluating PNT2002 for metastatic castration-resistant prostate cancer (mCRPC). This milestone was achieved ahead of schedule, showcasing the urgent need for new treatment options in this high-demand area. The next phase will enroll around 400 patients globally, with key endpoints focusing on radiographic progression-free survival and overall response rates. Results will be reported at a future scientific conference.
POINT Biopharma has entered a clinical supply agreement with Isotopia Molecular Imaging to supply no-carrier-added Lutetium-177 (n.c.a. Lu-177) for its radiopharmaceutical production facility in Indianapolis. Lu-177 is crucial for targeted radionuclide therapy in cancer treatments, particularly for metastatic castration-resistant prostate cancer. This agreement strengthens POINT's supply chain, essential for its clinical trials, as the product features a unique GMP production method. Isotopia aims to enhance global patient access to radiopharmaceutical therapies.